The RAS family of proteins are one of the hottest targets in cancer research despite being one of the hardest for drug hunters to hit. Revolution Medicines has raised $238 million in an IPO to finance development of therapies that it says can drug these molecules in a novel way.
On Wednesday evening, Revolution priced its offering of 14 million shares at $17 each, which was the high end of its revised price range. Last week, Revolution had set a preliminary target of 10 million shares priced in the range of $14 to $16 each. On Tuesday, the Redwood City, CA-based… Read more »
UNDERWRITERS AND PARTNERS
